Global Insights into the Achondroplasia Healthcare Market

According to Decision Advisors, the Global Achondroplasia Market Size is expected to grow from USD 148.6 million in 2025 to USD 675.1 million by 2035, at a CAGR of 16.34% during the forecast period 2025-2035. The global achondroplasia market is driven by the growing use of treatments that target specific diseases results in more patients receiving these specialized therapies, which change their disease progression. The most important treatment innovation is vosoritide, which acts as a C-type natriuretic peptide (CNP) analog that prevents excessive FGFR3 activity to enable normal bone development.